Medication info
Trajenta Duo Tablet 2.5/850 mg

Trajenta Duo Tablet 2.5/850 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Boehringer Ingelheim Korea
Appearance
Biconvex oval film-coated tablet in bright orange color
Packaging
60 tablets/box [(10 tablets/PTP packaging x 6)]
Approval status
Active

MFDS item code 201208291 · Approved 2012.11.15 · Insurance code 653501400

Summary

Main use
Improvement of blood glucose control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased up to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients not achieving adequate glycemic control with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start with their existing doses of linagliptin and metformin. 4. Patients not achieving adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Caution). 5. Patients not achieving adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may result in changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Patients in Whom This Medicine Must Not Be Used).

Ingredients

Importer
Boehringer Ingelheim Korea

Efficacy & effects

Improvement of blood glucose control in patients with type 2 diabetes

View approved original text

This medication is used to assist in blood sugar control for patients with type 2 diabetes when taken in combination with linagliptin and metformin. It helps manage blood sugar effectively in conjunction with dietary adjustments and exercise therapy. This contributes to maintaining stable blood sugar levels and plays a significant role in complementing patients' routine treatment for diabetes management. This medication is used to improve blood sugar control.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased up to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients not achieving adequate glycemic control with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start with their existing doses of linagliptin and metformin. 4. Patients not achieving adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Caution). 5. Patients not achieving adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may result in changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Patients in Whom This Medicine Must Not Be Used).

Precautions

This medication may rarely cause a serious side effect known as lactic acidosis due to one of its active ingredients, metformin hydrochloride. The risk of lactic acidosis increases in patients with impaired kidney function, or issues with heart or liver function, so those with such conditions should not take this medication. Additionally, this medication should not be administered to individuals with hypersensitivity to it, type 1 diabetes, diabetic ketoacidosis, severe kidney impairment, acute myocardial infarction, liver dysfunction, acute alcohol intoxication, women who are pregnant or breastfeeding. The dosage of this medication needs to be adjusted according to kidney function, and it should not be taken in cases of severe renal impairment. It is crucial to regularly check kidney function before and during treatment. Caution is advised when taken alongside sulfonylureas or insulin as there is a risk of hypoglycemia, and dosage adjustments may be necessary. During treatment with this medication, rare skin disorders such as acute pancreatitis or bullous pemphigoid may occur; hence, patients should promptly inform healthcare providers if severe abdominal pain or skin blisters appear. Long-term use may result in vitamin B12 deficiency, so if anemia or neurological symptoms develop, blood tests should be conducted to check vitamin B12 levels. This medication increases the risk of lactic acidosis when taken with alcohol, so alcohol consumption should be avoided. If iodinated contrast media is used during radiological examinations, there is a risk of impaired kidney function, therefore this medication should be stopped for a certain period before and after the examination, and kidney function reassessed. Elderly patients are at a higher risk of reduced kidney function, so dosage should be carefully adjusted and kidney function routinely monitored. Women who are pregnant or planning to become pregnant should avoid this medication, and it is also advised not to take it while breastfeeding. This medication is not recommended for children under 10 years old, and the safety and effectiveness in pediatric patients over 10 have not been sufficiently established. In cases of overdose, there is a risk of lactic acidosis, so immediate hospital treatment should be sought, and if necessary, the drug can be eliminated by hemodialysis. This medication should be kept out of the reach of children, stored in a dry place, and not transferred to another container. Finally, patients with or suspected of having mitochondrial disease should not use this medication, and if symptoms appear, treatment should be immediately discontinued, and a diagnosis should be sought.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • taste disturbance
  • cough
  • decreased appetite
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
Show 126 more
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficient vitamin B12
  • cheilitis
  • stomatitis
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • gastrointestinal disorders
  • cerebral infarction
  • speech disorders
  • Alzheimer-type dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • erectile dysfunction
  • goiter
  • anxiety
  • mood disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • androgenetic alopecia
  • hyperhidrosis
  • hair loss
  • pruritus
  • benign prostatic hyperplasia
  • vitreous hemorrhage
  • confusion state
  • nocturia
  • dermatitis
  • hypertension
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • stomatitis
  • mediastinitis
  • vocal cord polyp
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • dyspepsia
  • anal bleeding
  • dental caries
  • enteritis
  • gastritis
  • gingivitis
  • increased blood creatinine
  • facial edema
  • hyperthermia
  • back pain
  • osteoarthritis
  • limb pain
  • rotator cuff syndrome
  • dizziness
  • diabetic neuropathy
  • headache
  • subdural effusion
  • palpitations
  • dry eye
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • stress urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • hepatic steatosis
  • cholelithiasis
  • hearing loss
  • thyroid nodule

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be kept in a tightly sealed container to prevent exposure to air and moisture. Additionally, it is advisable to avoid storage in excessively hot or cold places and keep it at normal room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Biconvex oval film-coated tablet in bright orange color

Package unit

60 tablets/box [(10 tablets/PTP packaging x 6)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.